AR128464A1 - Péptidos agonistas duales glp-1 y glucagón con estabilidad biológica mejorada - Google Patents
Péptidos agonistas duales glp-1 y glucagón con estabilidad biológica mejoradaInfo
- Publication number
- AR128464A1 AR128464A1 ARP230100284A ARP230100284A AR128464A1 AR 128464 A1 AR128464 A1 AR 128464A1 AR P230100284 A ARP230100284 A AR P230100284A AR P230100284 A ARP230100284 A AR P230100284A AR 128464 A1 AR128464 A1 AR 128464A1
- Authority
- AR
- Argentina
- Prior art keywords
- improved biological
- biological stability
- dual glp
- agonist peptides
- glucagon agonist
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title abstract 2
- 102400000321 Glucagon Human genes 0.000 title abstract 2
- 108060003199 Glucagon Proteins 0.000 title abstract 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
- 102100040918 Pro-glucagon Human genes 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- 230000009977 dual effect Effects 0.000 title abstract 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
- 229960004666 glucagon Drugs 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002797 proteolythic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
En el presente documento se proporcionan agonistas duales de GLP-1 y glucagón con estabilidad biológica mejorada (por ejemplo, estabilidad proteolítica) y duración de acción. Los péptidos pueden administrarse, por ejemplo, una vez a la semana. Reivindicación 73: Una composición farmacéutica que comprende el péptido de una cualquiera de las reivindicaciones 1 - 72.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263307206P | 2022-02-07 | 2022-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128464A1 true AR128464A1 (es) | 2024-05-08 |
Family
ID=85198946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100284A AR128464A1 (es) | 2022-02-07 | 2023-02-07 | Péptidos agonistas duales glp-1 y glucagón con estabilidad biológica mejorada |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230357348A1 (es) |
| EP (1) | EP4476248A1 (es) |
| KR (1) | KR20240145499A (es) |
| CN (1) | CN118974080A (es) |
| AR (1) | AR128464A1 (es) |
| AU (1) | AU2023215655A1 (es) |
| CO (1) | CO2024012130A2 (es) |
| CR (1) | CR20240372A (es) |
| IL (1) | IL314635A (es) |
| MX (1) | MX2024009698A (es) |
| TW (1) | TW202346323A (es) |
| WO (1) | WO2023148366A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118546214B (zh) * | 2024-07-11 | 2024-12-03 | 中国药科大学 | Glp-1r受体激动多肽化合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI617574B (zh) | 2012-12-11 | 2018-03-11 | 梅迪繆思有限公司 | 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑 |
| SI2986313T1 (sl) * | 2013-04-18 | 2019-09-30 | Novo Nordisk A/S | Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo |
| WO2015086686A2 (en) * | 2013-12-13 | 2015-06-18 | Medimmune Limited | Protease resistant peptides |
| TWI726889B (zh) * | 2015-06-10 | 2021-05-11 | 英商梅迪繆思有限公司 | 蛋白酶抗性之脂化肽 |
| CN109195984A (zh) * | 2016-06-09 | 2019-01-11 | 免疫医疗有限公司 | 蛋白酶抗性的单-脂化肽 |
| TWI784968B (zh) | 2016-09-09 | 2022-12-01 | 丹麥商西蘭製藥公司 | 澱粉素類似物 |
-
2023
- 2023-02-02 TW TW112103706A patent/TW202346323A/zh unknown
- 2023-02-06 WO PCT/EP2023/052778 patent/WO2023148366A1/en active Application Filing
- 2023-02-06 KR KR1020247029795A patent/KR20240145499A/ko unknown
- 2023-02-06 CN CN202380031121.XA patent/CN118974080A/zh active Pending
- 2023-02-06 AU AU2023215655A patent/AU2023215655A1/en active Pending
- 2023-02-06 EP EP23703736.1A patent/EP4476248A1/en active Pending
- 2023-02-06 MX MX2024009698A patent/MX2024009698A/es unknown
- 2023-02-06 IL IL314635A patent/IL314635A/en unknown
- 2023-02-06 US US18/164,802 patent/US20230357348A1/en active Pending
- 2023-02-06 CR CR20240372A patent/CR20240372A/es unknown
- 2023-02-07 AR ARP230100284A patent/AR128464A1/es unknown
-
2024
- 2024-09-05 CO CONC2024/0012130A patent/CO2024012130A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202346323A (zh) | 2023-12-01 |
| WO2023148366A1 (en) | 2023-08-10 |
| KR20240145499A (ko) | 2024-10-07 |
| MX2024009698A (es) | 2024-08-19 |
| CN118974080A (zh) | 2024-11-15 |
| AU2023215655A1 (en) | 2024-08-22 |
| CO2024012130A2 (es) | 2024-09-30 |
| US20230357348A1 (en) | 2023-11-09 |
| EP4476248A1 (en) | 2024-12-18 |
| CR20240372A (es) | 2024-10-16 |
| IL314635A (en) | 2024-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211417A1 (es) | Analogos novedosos de glp-1 | |
| MX2020009856A (es) | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). | |
| CL2018003697A1 (es) | Interferón porcino pegilado y métodos de uso del mismo. | |
| PE20191716A1 (es) | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos | |
| AR079939A1 (es) | Composicion farmaceutica para tratar un sindrome metabolico | |
| PA8575701A1 (es) | Preparaciones acidas de insulina con estabilidad mejorada | |
| PE20200606A1 (es) | Composiciones solidas para administracion oral | |
| ECSP034624A (es) | Combinacion de agonista de gava e inhibidores de sorbitol-deshidrogenasa | |
| AR062775A1 (es) | Composicion farmaceutica capaz de mejorar la actividad de glp -1 en un ser humano y su uso para preparar un medicamento | |
| AR128464A1 (es) | Péptidos agonistas duales glp-1 y glucagón con estabilidad biológica mejorada | |
| CL2023000524A1 (es) | Compuestos fosfolípidos y usos de los mismos | |
| PE20221518A1 (es) | Analogos de incretina y sus usos | |
| CL2017002293A1 (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2 | |
| CO2023000097A2 (es) | Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral | |
| AR114324A1 (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
| PE20210116A1 (es) | Administracion oral de analogos del peptido glp-1 | |
| CO2023008676A2 (es) | Compuestos polipéptidos modificados con lactama | |
| AR114323A1 (es) | Péptidos de la cadena b de la relaxina modificados y su uso terapéutico | |
| CU20210105A7 (es) | Agonistas de il2 | |
| BR112021023012A2 (pt) | Coformulações injetáveis à base de ciclodextrina de inibidores de sglt2 e peptídeos de incretina | |
| CO2022004572A2 (es) | Tratamiento de la diabetes mellitus tipo 2 | |
| AR045074A1 (es) | Uso de cd164 soluble en desordenes inflamatorios y autoinmunes | |
| AR125905A1 (es) | Agonistas del receptor del péptido-1 similar al glucagón | |
| AR119324A1 (es) | Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1 | |
| CO2023008101A2 (es) | Formulaciones de péptidos terapéuticos |